Lexaria Bioscience Corp. (LEXX)

3,0501 -0,4399 (-12,60%) Ab 02:17PM EDT. Markt geöffnet.

Lexaria Bioscience Corp.

740 McCurdy Road
Suite 100
Kelowna, BC V1X 2P7
Canada
250 765 6424
https://lexariabioscience.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 5

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher A. Bunka	Chairman & CEO	291,19k	N/A	1962
Mr. John M. Docherty M.Sc.	President & Director	290,46k	N/A	1969
Mr. Nelson D. Cabatuan CPA	Chief Financial Officer	N/A	N/A	1979
Kristin Hamilton	Director of Operations	N/A	N/A	N/A
Vanessa Carle	Head of Legal	N/A	N/A	N/A
Dr. Philip N. Ainslie Ph.D.	Advisor & Consultant	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Corporate Governance

Lexaria Bioscience Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.